Canada markets open in 7 hours 31 minutes

Arch Biopartners Inc. (ACHFF)

OTC Markets OTCPK - OTC Markets OTCPK Delayed Price. Currency in USD
Add to watchlist
1.2200-0.0100 (-0.81%)
At close: 03:57PM EDT

Arch Biopartners Inc.

27 Street Clair Avenue East
PO Box 305
Toronto, ON M4T 2M5

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Richard Gabriel MuruveCo-Founder, CEO, President & Director109.9kN/A1971
Dr. Daniel Abraham Muruve M.D.Co-Founder, Chief Science Officer & Member of Scientific Advisory BoardN/AN/AN/A
Mr. Andrew Bishop CFACFO & DirectorN/AN/A1966
Dr. Justin MacDonald Ph.D.Co-Founder & Principal ScientistN/AN/AN/A
Dr. Paul BeckCo-Founder & Principal ScientistN/AN/AN/A
Mr. Aaron BensonDirector of CommunicationsN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Arch Biopartners Inc., together with its subsidiaries, engages in the development of therapeutic drugs for inflammation and acute organ injuries in Canada. It focuses on developing its lead drug candidate LSALT Peptide, a product in Phase 2 clinical trials to treat dipeptidase-1 mediated organ inflammation in the lungs, liver, and kidneys. The company also develops AB569 for treating antibiotic-resistant bacterial infections, and for the treatment of wounds; and Borg, a peptide-solid surface interface to reduce corrosion of metals. Arch Biopartners Inc. is based in Toronto, Canada.

Corporate Governance

Arch Biopartners Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.